These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 11486314)

  • 1. Immunotherapy of multiple myeloma.
    Ruffini PA; Kwak LW
    Semin Hematol; 2001 Jul; 38(3):260-7. PubMed ID: 11486314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent advances in multiple myeloma immunotherapy.
    Ruffini PA; Biragyn A; Kwak LW
    Biomed Pharmacother; 2002 May; 56(3):129-32. PubMed ID: 12046683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dendritic cells in clinical trials for multiple myeloma.
    Reichardt VL; Brossart P
    Methods Mol Med; 2005; 109():127-36. PubMed ID: 15585918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: immunological and clinical aspects.
    Titzer S; Christensen O; Manzke O; Tesch H; Wolf J; Emmerich B; Carsten C; Diehl V; Bohlen H
    Br J Haematol; 2000 Mar; 108(4):805-16. PubMed ID: 10792287
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy in multiple myeloma: current strategies and future prospects.
    Yi Q
    Expert Rev Vaccines; 2003 Jun; 2(3):391-8. PubMed ID: 12903804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Growth inhibition of myeloma cells by anti-idiotype antibodies in the absence of membrane-bound immunoglobulin.
    Moshitzky S; Kukulansky T; Haimovich J; Hollander N
    Immunol Cell Biol; 2008; 86(3):261-7. PubMed ID: 18195726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Idiotype immunity (natural and vaccine-induced) in early stage multiple myeloma.
    Osterborg A; Henriksson L; Mellstedt H
    Acta Oncol; 2000; 39(7):797-800. PubMed ID: 11145435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful generation of sperm protein 17 (Sp17)-specific cytotoxic T lymphocytes from normal donors: implication for tumour-specific adoptive immunotherapy following allogeneic stem cell transplantation for Sp17-positive multiple myeloma.
    Chiriva-Internati M; Wang Z; Salati E; Wroblewski D; Lim SH
    Scand J Immunol; 2002 Oct; 56(4):429-33. PubMed ID: 12234264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapeutic strategies for the treatment of plasma cell malignancies.
    Treon SP; Raje N; Anderson KC
    Semin Oncol; 2000 Oct; 27(5):598-613. PubMed ID: 11049026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of human idiotype-specific T cells in lymphoma and myeloma.
    Weng J; Neelapu SS; Woo AF; Kwak LW
    Curr Top Microbiol Immunol; 2011; 344():193-210. PubMed ID: 20549471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Idiotype-specific immunotherapy in multiple myeloma: suggestions for future directions of research.
    Bogen B; Ruffini PA; Corthay A; Fredriksen AB; Frøyland M; Lundin K; Røsjø E; Thompson K; Massaia M
    Haematologica; 2006 Jul; 91(7):941-8. PubMed ID: 16818282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Active immunotherapy of multiple myeloma.
    Houet L; Veelken H
    Eur J Cancer; 2006 Jul; 42(11):1653-60. PubMed ID: 16797966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
    Ruffini PA; Neelapu SS; Kwak LW; Biragyn A
    Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Idiotypic vaccination in B-cell malignancies.
    Bianchi A; Massaia M
    Mol Med Today; 1997 Oct; 3(10):435-41. PubMed ID: 9358470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy for the treatment of multiple myeloma.
    Jung SH; Lee HJ; Vo MC; Kim HJ; Lee JJ
    Crit Rev Oncol Hematol; 2017 Mar; 111():87-93. PubMed ID: 28259300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NY-ESO-1 immunotherapy for multiple myeloma.
    Szmania S; Tricot G; van Rhee F
    Leuk Lymphoma; 2006 Oct; 47(10):2037-48. PubMed ID: 17071474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dendritic cell immunotherapy for cancer: application to low-grade lymphoma and multiple myeloma.
    Hart DN; Hill GR
    Immunol Cell Biol; 1999 Oct; 77(5):451-9. PubMed ID: 10540212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting heat shock proteins for immunotherapy in multiple myeloma: generation of myeloma-specific CTLs using dendritic cells pulsed with tumor-derived gp96.
    Qian J; Wang S; Yang J; Xie J; Lin P; Freeman ME; Yi Q
    Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8808-15. PubMed ID: 16361569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of cellular immune responses in patients with stage-I multiple myeloma after vaccination with autologous idiotype-pulsed dendritic cells.
    Röllig C; Schmidt C; Bornhäuser M; Ehninger G; Schmitz M; Auffermann-Gretzinger S
    J Immunother; 2011 Jan; 34(1):100-6. PubMed ID: 21150718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimizing dendritic cell-based immunotherapy in multiple myeloma.
    Yi Q; Desikan R; Barlogie B; Munshi N
    Br J Haematol; 2002 May; 117(2):297-305. PubMed ID: 11972511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.